Welcome to our dedicated page for Tempest Therapeutics news (Ticker: TPST), a resource for investors and traders seeking the latest updates and insights on Tempest Therapeutics stock.
Tempest Therapeutics, Inc. develops clinical-stage cell therapy and small-molecule product candidates for cancer and related disease areas. News about TPST centers on its dual-targeting CAR-T platform, including TPST-2003, a CD19/BCMA CAR-T therapy under development for relapsed or refractory multiple myeloma, and clinical updates from programs such as REDEEM-1 and POEMS-1.
Company updates also cover CAR-T manufacturing and technology-transfer work, partner-supported development activities, business development and licensing priorities, and the amezalpat small-molecule program. Recurring corporate news includes financial results, pipeline portfolio changes following acquired CAR-T assets, leadership appointments, and governance or capital-structure matters tied to the company’s Nasdaq-listed common stock.
Tempest Therapeutics, Inc. (NASDAQ: TPST) announced the successful merger with Millendo Therapeutics, effective June 28, 2021. The merger facilitated a $30 million PIPE financing from notable healthcare investors, providing essential funds for advancing Tempest's clinical programs, including TPST-1495 and TPST-1120 through Phase 1 studies. Following the merger, a 1:15 reverse stock split was executed, resulting in approximately 6.7 million shares outstanding. Important board updates were made, positioning Tempest for future growth as it aims to deliver innovative cancer therapies.